Kropff, M., Goranov, S. Thalidomide versus dexamethasone for the treatment of relapsed and/or refractory multiple myeloma: results from OPTIMUM, a randomized trial. Pavia: 2012 784-791,.
Kropff, M., Goranov, S. Thalidomide versus dexamethasone for the treatment of relapsed and/or refractory multiple myeloma: results from OPTIMUM, a randomized trial. Pavia: 2012 784-791,.
Kropff, M., Goranov, S. (2012) Thalidomide versus dexamethasone for the treatment of relapsed and/or refractory multiple myeloma: results from OPTIMUM, a randomized trial, Pavia: 784-791,.
Kropff, M., & Goranov, S. (2012). Thalidomide versus dexamethasone for the treatment of relapsed and/or refractory multiple myeloma: results from OPTIMUM, a randomized trial. Pavia: 784-791.
Kropff M, Goranov S. Thalidomide versus dexamethasone for the treatment of relapsed and/or refractory multiple myeloma: results from OPTIMUM, a randomized trial. Pavia: 2012. p. 784-791.